Life after ESPRIT: which first-line antiplatelet treatment should we use?
Gorelick
Philip B
PB
Department of Neurology and Rehabilitation, Center for Stroke Research, University of Illinois College of Medicine at Chicago, Chicago, IL 60612, USA. pgorelic@uic.edu
D002986:Clinical Trials as Topic; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D020521:Stroke / Q000188:drug therapy / Q000517:prevention & control*
D010975:Platelet Aggregation Inhibitors